NASDAQ:HRMY Harmony Biosciences Q3 2026 Earnings Date & Estimates $39.60 +0.26 (+0.66%) Closing price 04:00 PM EasternExtended Trading$39.63 +0.03 (+0.08%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Harmony Biosciences is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 3, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Harmony Biosciences in Q3 2026Harmony Biosciences is expected to post earnings of $1.11 per share on revenue of $274.55 million. In the same quarter a year earlier Harmony Biosciences reported $0.87 per share on revenue of $239.46 million. Harmony Biosciences last reported on August 4, 2026, posting $1.28 per share and beating the $0.96 consensus estimate. Harmony Biosciences has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS$1.11Expected Revenue$274.55 millionPrior-Year EPS$0.87Prior-Year Revenue$239.46 millionExpected EPS Growth+27.6%Expected Revenue Growth+14.7%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$1.28 (Beat by +$0.32)Last Quarter Revenue$261.28 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Harmony Biosciences Q3 2026 Earnings FAQ When does Harmony Biosciences report Q3 2026 earnings? Harmony Biosciences (NASDAQ:HRMY) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. What time is Harmony Biosciences' Q3 2026 earnings call? Harmony Biosciences' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Harmony Biosciences? Analysts expect Harmony Biosciences to post earnings of $1.11 per share for Q3 2026. How much revenue is Harmony Biosciences expected to report? The consensus revenue estimate for Harmony Biosciences is $274.55 million for Q3 2026. Harmony Biosciences Earnings HeadlinesHarmony BioSciences' Wakix Franchise, Pipeline Offer Multiple Value Drivers, Oppenheimer Says3 hours ago | finance.yahoo.comHarmony Biosciences (HRMY) Stock Looks Below Fair Value As Shares Rose 48%3 hours ago | finance.yahoo.comThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.October 8 at 1:00 AM | Base Camp Trading (Ad)Harmony Biosciences Holdings, Inc. Announces Poster Presentation Featuring Information From Ongoing Phase 3 Trials Of HBS-301October 3, 2026 | marketscreener.comMDeutsche Bank Lifts Price Target on Harmony Biosciences Holdings to $42 From $39, Keeps Hold RatingOctober 1, 2026 | marketscreener.comMHarmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy DaysOctober 1, 2026 | globenewswire.comSee More Harmony Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Harmony Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harmony Biosciences and other key companies, straight to your email. Email Address About Harmony BiosciencesHarmony Biosciences (NASDAQ:HRMY) is a commercial-stage pharmaceutical company focused on developing and marketing therapies for patients with rare neurological disorders. The company’s activities center on conditions that are often underserved by conventional treatment options, including sleep disorders and other central nervous system diseases. Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled medication that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved to treat excessive daytime sleepiness or cataplexy in adults with narcolepsy and is also approved for certain pediatric patients with narcolepsy. The company continues to evaluate additional applications and investigational therapies addressing neurological conditions. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences primarily serves the U.S. market through its commercial and medical operations. The company is led by Jeffrey M. Dayno, M.D., who serves as president and chief executive officer and has experience in neurology, sleep medicine and pharmaceutical development.View Harmony Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
